I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability And Reporting Limitations.............. I-1
Disclaimers .................................................. I-2
Data Interpretation & Reporting Level........................ I-2
Quantitative Techniques & Analytics.......................... I-3
Product Definition And Scope Of Study.................. I-3
HbA1c Laboratory Testing ..................................... I-3
HbA1c Point Of Care Testing & Self-Monitoring ........ I-4

II. EXECUTIVE SUMMARY

1. Market Overview ............................................... II-1
   Current and Future Analysis................................ II-1
   Regional Analysis............................................ II-1
   Analysis by Product Segments.............................. II-2
   Diabetes Monitoring Market................................ II-2
   Higher Levels of Glycosylated Hemoglobin Increases
   the Risk of Death............................................. II-2
   Regular HbA1c Test Keeps Heart Risk at Bay........ II-2
   Home Monitoring............................................. II-3

2. Product Overview............................................. II-4
   Product Definition.......................................... II-4
   HbA1c Monitoring.............................................. II-4
   What is A1C.................................................. II-4
   Hemoglobin A1C (HbA1c) Test............................... II-4
   Interpreting HbA1c Test Readings...................... II-5
   Table 1: Interpreting HbA1c Test Readings.......... II-5
   Result of Hemoglobin A1c Test.......................... II-6
   Advantages of A1c Assessment & Interpretation......... II-6
   Risks Associated with HbA1c Testing................... II-6
   Methods of Measurement for Glycohemoglobin........ II-6
   The Diabetes Control & Complications Trial (DCCT).... II-7
   The Kumamoto and UK Prospective Studies............. II-7
   Glycemia Tests Used in Monitoring Diabetes........ II-7
   Urine Glucose Testing..................................... II-7
   Glycated Protein Testing.............................. II-8
   Table 2: Relation Between A1C Level and
   Mean Plasma Glucose Levels................................. II-8
   HbA1c Test Types............................................. II-8
   HbA1c Laboratory Testing................................ II-9
   HbA1c Laboratory Testing Product Development
   Over the Years............................................. II-9
   HbA1c Point Of Care Testing & Self-Monitoring........ II-10
   POCT HbA1c Testing Market (2004 E).................. II-12
   POCT & Self-Monitoring Product Developments:
   (2000-2003)........................................... II-13

3. Diabetes - A Brief Profile of the Disease............ II-15
   What Causes Diabetes.................................... II-15
   Types of Diabetes........................................ II-15
   Major Types of Diabetes................................ II-16

4. Research and Development Highlights............... II-22
   G5 Diabetes Diagnostic Test by Provalis............. II-22
   Diabetes Risk Among Young Native Americans...... II-22
   Mean HbA1c Scores at National Level.................. II-22
   Short Term Economic Benefits of Enhanced Glycemic
   Control.................................................. II-22

5. Technological Developments............................. II-24
   New Noninvasive Monitoring and Testing Devices.... II-24
   HGI as a Statistical Predictor of Nephropathy...... II-24
   micro-Optical Detection Method Technology - Metrika...II-25

6. Regulatory Environment- What’s New................ II-26
   Axis-Shield’s Afinion™ System Obtains FDA
   CLIA Waiver................................................ II-26
   Diazyme’s Enzymatic HbA1c Assay Receives
   NGSP Accreditation........................................ II-26
   Axis-Shield Obtains FDA Clearance for Afinion
   and Afinion HbA1c Test...................................... II-26
   Axis-Shield Obtains NGSP Accreditation for Afinion
   HbA1c Test............................................ II-26
   Abbott Laboratories and Seradyn Obtain US FDA
   Approval for Hemoglobin A1c Assay..................... II-26

Likely Complications.............................................. II-16
Nephropathy (Kidney Disease)............................. II-16
Diabetic Neuropathy (Nerve Damage)..................... II-16
Retinopathy (Damage to the Eye and Blindness)........ II-17
Poor Healing of Infections and Wounds.................. II-17
Impotence in Men.................................................. II-17
Periodontal Disease............................................ II-17
Cardiovascular Disease.................................... II-17
Interpreting the A1c Range................................. II-17
Blood Glucose Level Guidelines* in the US............. II-18
Overview of Diabetes Care Market in the 1990s........ II-18
Future Outlook................................................ II-18

Table 3: World Diabetes and Population Statistics
(2003 & 2025).................................................. II-18
Prevalence of Diabetes in Various Parts of the World....II-19

Table 4: World Diabetes Market (2000 & 2030): Breakup
by Regions Having the Highest Number of People with
Diabetes - India, China, US, Indonesia, Japan, Pakistan,
Russian Federation, Brazil, Italy, Bangladesh, Philippines
and Egypt (in million) (includes corresponding
Graph/Chart).................................................. II-19

Table 5: Diabetes Treatment Options in the US:
Percentage Breakdown for Insulin or Insulin &
Oral Drugs, Oral Drugs, and Diet & Exercise
(includes corresponding Graph/Chart).................. II-21

Table 6: Side Effects of Insulin Therapy................. II-21
Maintaining A1c Test Result Below 7%..................... II-21
Common Diabetes Management Practices............. II-21

This Document May Not Be Printed, Copied or Distributed Outside Your Organization in Any Form Without Our Express Written Permission
HEMOGLOBIN A1c MONITORING
A GLOBAL STRATEGIC BUSINESS REPORT

CONTENTS

Medicare Reform Act Passed for Reforms in Diabetes Treatment and Care in the US........................................II-27
Bio-Rad Obtains FDA Approval for D-10 Hemoglobin A1c System..................................................II-27
FDA Approves OTC Diabetes Test and Clears Metrika’s A1cNow™ Diabetes Monitor for Home Use.........II-27
FDA Level 1 Certification for SimpleChoice A1c Test Device........................................................................II-27
Metrika Obtains FDA Approval for Digital Response® HbA1c Patient Monitor........................................II-28

7. Product Innovations/Introductions................................II-29
OrSense Introduces Non-Invasive Hematocrit/ Hemoglobin Sensor ....................................................II-29
Bayer to Divest Diagnostic Division of Bayer Healthcare to Siemens ........................................................II-29
Primus Corp Rolls Out Ultra2™ A1c, an HPLC system .................................................................II-29
Axis-Shield Introduces AFINION, New POC Test System .............................................................II-29
Bristol-Myers Squibb Launches Choice DM™ A1C Home Test ............................................................II-30
Beckton Launches FDA Approved Products for Diabetes Management ................................................II-30
International Technidyne Rolls Out Hgb Pro Professional Hemoglobin Testing System™ ..................II-30
Bayer Unveils HbA1C Assay for the ADVIA® 1650 Chemistry System ...............................................II-30
Catachem Launches Glycated Hemoglobin In-Vitro Diagnostic Kit .....................................................II-31
Beijing Blue Cross Biotech Launches Colibri System .............................................................................II-31
Cholestech Obtains Clearance to Market Cholestech GDXT™ System in Canada .........................II-31
SpectRx Announces Launch of SimpleChoice® Products .................................................................II-31
DCA 200+ Analyzer Minimizes Risk and Helps to Monitor HbA1c Levels ........................................II-31
BioSafe Laboratory Introduces BioSafe HbA1c Test Kit .....................................................................II-31
FlexSite Diagnostics, Inc. Launches A1c at Home™ Test Kit .............................................................II-32
Integrated Technologies Launched ABAKA to Measure Glib ............................................................II-32
Provalis Develops Glycoal ......................................................II-32

8. Recent Industry Activity ........................................II-33
Bio-Rad Laboratories Inks Multi-year Contract with Premier ..........................................................II-33
Trinity Biotech Acquires Primus Corp ..................................................................................................II-33
Axis-Shield Obtains Approval for AFINION™..................................................................................II-33
Abbott Laboratories and Seradyn Receive FDA Clearance for Multigent™ Hemoglobin A1c Test ....II-33
Shanghai Upper Biotech Signs Agreement with Chinese Ministry of Health ..................................II-34
Roche Acquires Insulin Pump Unit of Disetronic ................................................................................II-34
Becton Dickinson Diversifies into Blood-Glucose Meter Products.................................................II-34
Sysmex Corp Pens Distribution Agreement with Bio-Rad ..............................................................II-34
Tosoh Medics Adopts New Corporate Identity ...............................................................................II-35
G5 to Enter Trials in the US........................................................................................................II-35

Cholestech Signs Global Distribution Agreement with Provalis ..................................................II-36
BioSafe Announces Distribution of Free and Low-Cost HbA1c Tests ..............................................II-36
Tosoh and Sysmex Sign Sales Agreement .....................................................................................II-36
Bayer Diagnostics Pens Co-Marketing Agreement with Cholestech Corporation .......................II-36
Provalis Obtains US Patent for Glycoal ...........................................................................................II-36
Axis-Shield Plc Acquires Nycomed Diagnostics .............................................................................II-36
Quest Selects COBAS Integra Hemoglobin A1c Assay from Roche .........................................II-36

9. Focus on Select Global Players................................II-37
Abbott Laboratories (USA) ........................................................................................................II-37
Axis-Shield (UK) ....................................................................................................................II-37
Bayer (Germany) ...................................................................................................................II-37
Beckman Coulter, Inc. (US) ........................................................................................................II-38
Bio-Rad Laboratories Inc (USA) .....................................................................................................II-39
Biosafe Laboratories Inc (USA) ......................................................................................................II-39
Diabetes Technologies Inc (USA) ....................................................................................................II-39
Flexsite Diagnostics Inc (USA) ........................................................................................................II-40
Metrika Inc (USA) ........................................................................................................................II-40
Primus Corporation (USA) .............................................................................................................II-40
Provalis Plc (UK) ........................................................................................................................II-41
Roche Diagnostics (Switzerland) ..................................................................................................II-41
SpectRx Inc. (USA) ........................................................................................................................II-41
Tosoh Bioscience, Inc (USA) ........................................................................................................II-41

10. Global Market Perspective ....................................II-42
Table 6: World Recent Past, Current and Future Analysis for HbA1c Monitoring by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), the Middle East, Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart) ........................................................................II-42
Table 7: World 11-Year Perspective for HbA1c Monitoring by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), the Middle East and Latin America and Rest of World Markets for Years 2000, 2005, 2010 (includes corresponding Graph/Chart) ........................................................................II-43
Table 8: World Recent Past, Current and Future Analysis for HbA1c Laboratory Testing by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), the Middle East and Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart) ........................................................................II-44
Table 9: World 11-Year Perspective for HbA1c Laboratory Testing by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), the Middle East and Latin America and Rest of World Markets for Years 2000, 2005, 2010 (includes corresponding Graph/Chart) ........................................................................II-45
#### III. MARKET

**1. The United States**

<table>
<thead>
<tr>
<th>Table 12:</th>
<th>HbA1c Point of Care and Self-Monitoring by Test Types - HbA1c Laboratory Testing and HbA1c Point of Care and Self-Monitoring Markets Independently Analyzed with Annual Sales Figures in US$ Million for the Years 2000, 2005, 2010 (includes corresponding Graph/Chart)</th>
<th>III-20</th>
</tr>
</thead>
<tbody>
<tr>
<td>Table 13:</td>
<td>HbA1c Laboratory Testing Market in the US (2002-2005): Market Shares by Sales for Bio-Rad, Roche, Tosoh, Bayer, and Others (includes corresponding Graph/Chart)</td>
<td>III-4</td>
</tr>
<tr>
<td>Diabetes: The Statistics</td>
<td></td>
<td>III-3</td>
</tr>
<tr>
<td>Age Factor</td>
<td></td>
<td>III-3</td>
</tr>
<tr>
<td>Table 14:</td>
<td>US Market for Diabetes (2005 E): Percentage Breakdown of Prevalence by Age Group - 20-44 years, 45-64 years, 65-74 years and 75 years + (includes corresponding Graph/Chart)</td>
<td>III-4</td>
</tr>
<tr>
<td>Prevalence by Race/Ethnicity</td>
<td></td>
<td>III-4</td>
</tr>
<tr>
<td>Table 15:</td>
<td>US Market for Diabetes (2004 E): Percentage Breakdown of Prevalence by Race/Ethnicity- American Indians/Alaska Natives, Non-Hispanic Blacks, Hispanic/Latin Americans and Non-Hispanic Whites (includes corresponding Graph/Chart)</td>
<td>III-4</td>
</tr>
<tr>
<td>Table 16:</td>
<td>Prevalence of Diabetes in Americans 20 Years or Over by Race/Ethnicity and Gender (includes corresponding Graph/Chart)</td>
<td>III-5</td>
</tr>
<tr>
<td>Diabetes Statistics in the Recent Past - A Review</td>
<td></td>
<td>III-5</td>
</tr>
<tr>
<td>Table 17:</td>
<td>Prevalence Estimates of Diabetes Mellitus in the US: 2000-01</td>
<td>III-5</td>
</tr>
</tbody>
</table>

**2. Canada**

| Table 20: | US Recent Past, Current and Future Analysis for HbA1c Monitoring by Test Types - HbA1c Laboratory Testing and HbA1c Point of Care and Self-Monitoring Markets Independently Analyzed with Annual Sales Figures in US$ Million for the Years 2000, 2005, 2010 (includes corresponding Graph/Chart) | III-20 |

| Table 18: | Prevalence Estimates of Type 1 Diabetes Mellitus in the US: 2000-01 | III-5 |
| Table 19: | Diabetic Cases in the US in 2000 by State | III-5 |
HEMOGLOBIN A1c MONITORING
A GLOBAL STRATEGIC BUSINESS REPORT


4. Japan ............................................................................ III-23
A. Market Overview........................................................... III-23
Current and Future Analysis........................................ III-23
Industry Activity in the Recent Past............................. III-23
Key Japanese Player..................................................... III-24
B. Market Analytics ........................................................... III-24

Table 26: Japanese Recent Past, Current and Future Analysis for HbA1c Monitoring by Test Types - HbA1c Laboratory Testing and HbA1c Point of Care and Self-Monitoring Markets Independently Analyzed with Annual Sales Figures in USS Million for Years 2000 through 2010 (includes corresponding Graph/Chart)........................................ III-24


4. France ........................................................................... III-30
A. Market Overview........................................................... III-30
Current and Future Analysis........................................ III-30
B. Market Analytics ........................................................... III-30

Table 34: French Recent Past, Current and Future Analysis for HbA1c Monitoring by Test Types - HbA1c Laboratory Testing and HbA1c Point of Care and Self-Monitoring Markets Independently Analyzed with Annual Sales Figures in USS Million for Years 2000 through 2010 (includes corresponding Graph/Chart)............................ III-30


4b. Germany ....................................................................... III-31
A. Market Overview........................................................... III-31
Current and Future Analysis........................................ III-31
B. Market Analytics ........................................................... III-31

Table 36: German Recent Past, Current and Future Analysis for HbA1c Monitoring by Test Types - HbA1c Laboratory Testing and HbA1c Point of Care and Self-Monitoring Markets Independently Analyzed with Annual Sales Figures in USS Million for Years 2000 through 2010 (includes corresponding Graph/Chart)............................ III-31

Table 37: German 11-Year Perspective for HbA1c Monitoring by Test Types- Percentage Breakdown of Dollar Sales for HbA1c Laboratory Testing and HbA1c Point of Care and Self-Monitoring Markets for 2000, 2005, 2010 ........................................ III-31

4c. Italy ............................................................................. III-32
A. Market Overview........................................................... III-32
Current and Future Analysis........................................ III-32
B. Market Analytics ........................................................... III-32

Table 38: Italian Recent Past, Current and Future Analysis for HbA1c Monitoring by Test Types - HbA1c Laboratory Testing and HbA1c Point of Care and Self-Monitoring Markets Independently Analyzed with Annual Sales Figures in USS Million for Years 2000 through 2010 (includes corresponding Graph/Chart)............................ III-32
CONTENTS

4d. The United Kingdom .................................................. III-33
   A. Market Overview .......................................................... III-33
   Current and Future Analysis ........................................... III-33
   Key Statistics ............................................................... III-33
   Product Innovations/Introductions .................................. III-33
   Recent Industry Activity ............................................... III-34
   Key Players in the UK .................................................... III-35
   B. Market Analytics .......................................................... III-37
   Table 40: UK Recent Past, Current and Future Analysis for HbA1c Monitoring by Test Types - HbA1c Laboratory by Testing and HbA1c Point of Care and Self-Monitoring Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart) ............. III-37

4e. Spain ........................................................................ III-38
   A. Market Overview .......................................................... III-38
   Current and Future Analysis ........................................... III-38
   B. Market Analytics .......................................................... III-38
   Table 42: Spanish Recent Past, Current and Future Analysis for HbA1c Monitoring by Test Types - HbA1c Laboratory Testing and HbA1c Point of Care and Self-Monitoring Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart) ............. III-38

4f. Russia ...................................................................... III-39
   A. Market Overview .......................................................... III-39
   Current and Future Analysis ........................................... III-39
   B. Market Analytics .......................................................... III-39
   Table 44: Russian Recent Past, Current and Future Analysis for HbA1c Monitoring by Test Types - HbA1c Laboratory Testing and HbA1c Point of Care and Self-Monitoring Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart) ............. III-39

4g. Rest of Europe ...................................................... III-40
   A. Market Overview .......................................................... III-40
   Current and Future Analysis ........................................... III-40
   Key Player ................................................................. III-40
   Industry Activity in the Recent Past ................................ III-40
   B. Market Analytics .......................................................... III-41
   Table 46: Rest of Europe Recent Past, Current and Future Analysis for HbA1c Monitoring by Test Types - HbA1c Laboratory Testing and HbA1c Point of Care and Self-Monitoring Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart) ............. III-41
   Table 47: Rest of Europe 11-Year Perspective for HbA1c Monitoring by Test Types- Percentage Breakdown of Dollar Sales for HbA1c Laboratory Testing and HbA1c Point of Care and Self-Monitoring Markets for 2000, 2005, 2010 .......... III-41

5. Asia-Pacific ........................................................... III-42
   A. Market Overview .......................................................... III-42
   Current and Future Analysis ........................................... III-42
   Diabetes Prevalence Rates in the Asia-Pacific Region .... III-42
   Table 48: Prevalence Estimates of Diabetes Mellitus in South-East Asia: 2000-01 .......... III-43
   Table 49: Prevalence Estimates of Type 1 Diabetes Mellitus in Southeast Asia: 2000-01 .......... III-43
   Table 50: Prevalence Estimates of Diabetes Mellitus in Western Pacific: 2000-01 .......... III-44
   Recent Industry Activity ................................................. III-44
   B. Market Analytics .......................................................... III-45
   Table 51: Asia Pacific Recent Past, Current and Future Analysis for HbA1c Monitoring by Test Types - HbA1c Laboratory Testing and HbA1c Point of Care and Self-Monitoring Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart) ............. III-45

6. The Middle East ..................................................... III-46
   A. Market Overview .......................................................... III-46
   Current and Future Analysis ........................................... III-46
   Table 53: Prevalence Estimates of Diabetes Mellitus in the Middle East in 2000-01 .......... III-46
CONTENTS

A. Market Overview ............................................................. III-49
    Current and Future Analysis ........................................... III-49
    Diabetes Statistics in Latin America ........................... III-49

B. Market Analytics ............................................................. III-48
    Table 55: Middle East Recent Past, Current and Future Analysis for HbA1c Monitoring by Test Types - HbA1c Laboratory Testing and HbA1c Point of Care and Self-Monitoring Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart) ............... III-48
    Table 56: Middle East 11-Year Perspective for HbA1c Monitoring by Test Types - Percentage Breakdown of Dollar Sales for HbA1c Laboratory Testing and HbA1c Point of Care and Self-Monitoring Markets for 2000, 2005, 2010 ............................................... III-48

7. Latin America ................................................................. III-49
A. Market Overview ............................................................. III-49
    Current and Future Analysis ........................................... III-49
    Diabetes Statistics in Latin America ........................... III-49

B. Market Analytics ............................................................. III-48
    Table 57: Prevalence of Diabetes Complications in South & Central American Region: 2004 E ............................................. III-49
    Table 58: Prevalence of Diabetes Mellitus in South & Central America: 2000-01 .................................................. III-50
    Table 59: Prevalence of Type 1 Diabetes Mellitus in South & Central America: 2000-01 .................................................. III-51
    Table 60: Prevalence of Diabetes Mellitus in Mexico: 2000-01 .................................................. III-51
    Table 61: Prevalence Estimates of Type 1 Diabetes Mellitus in Mexico: 2000-01 .................................................. III-51

IV. COMPETITION

1. A. Menarini Diagnostics (Italy) ........................................ IV-1
2. Abbott Laboratories (USA) .............................................. IV-3
    Table 70: Annual Sales Analysis By Quarter: 2003-2004 (In US$ Billion) .................................................. IV-5
    Table 71: Annual Sales Analysis By Segment: 2003-2004 (In US$ Billion) .................................................. IV-6
    Table 72: Annual Sales Analysis By Geographic Region: 2003-2004 (In US$ Billion) .................................................. IV-6
    Abbott Diagnostics (USA) .............................................. IV-12
    AbbVie GmbH & Co., KG (Germany) ............................ IV-21
3. Accutech LLC (USA) ........................................................ IV-23
4. Arkray, Inc. (Japan) ................................................... IV-24
5. Axis-Shield Plc (UK) ................................................... IV-25
    Table 73: Annual Sales Analysis: 2003-2005 (In £ Million) .................................................. IV-25
    Table 74: Annual Sales Analysis By Segment: 2004-2005 (In £ Million) .................................................. IV-26
6. Bayer Healthcare - Diagnostics GmbH (Germany) .......... IV-28
7. Beckman Coulter, Inc. (USA) ............................................ IV-29
8. Beckman Coulter, Inc. (USA) ............................................ IV-29
    Table 75: First Quarter Sales Analysis: 2005-2006 (In US$ Million) .................................................. IV-32
    Table 76: Annual Sales Analysis: 2004-2005 (In US$ Million) .................................................. IV-36
    Table 77: Annual Sales Analysis By Segment: 2004-2005 (In US$ Million) .................................................. IV-36

8. Rest of the World ............................................................. III-53
A. Market Overview ............................................................. III-53
    Current and Future Analysis ........................................... III-53
    Key Diabetes Statistics in Africa .................................. III-53
    Diabetes Prevalence Rates in Africa ........................... III-53
    Table 64: Prevalence Estimates of Diabetes Mellitus in Africa: 2000-01 .................................................. III-54
    Table 65: Prevalence Estimates of Type 1 Diabetes Mellitus in Africa: 2000-01 .................................................. III-55

B. Market Analytics ............................................................. III-56
    Table 66: Rest of World Recent Past, Current and Future Analysis for HbA1c Monitoring by Test Types - HbA1c Laboratory Testing and HbA1c Point of Care and Self-Monitoring Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart) ............... III-56
    Table 67: Rest of World 11-Year Perspective for HbA1c Monitoring by Test Types - Percentage Breakdown of Dollar Sales for HbA1c Laboratory Testing and HbA1c Point of Care and Self-Monitoring Markets for 2000, 2005, 2010 ............................................... III-56
CONTENTS

Table 78: Annual Sales Analysis By Geographic Region: 2004-2005 (In US$ Million) .............................. IV-36
8. Becton Dickinson and Company (USA) ......................... IV-39

Table 79: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ Million) ........................................ IV-41
Table 80: Half Yearly Sales Analysis By Quarter: 2005-2006 (H1) (In US$ Million) .............................. IV-41
Table 81: Half Yearly Sales Analysis By Segment: 2005-2006 (H1) (In US$ Million) ............................ IV-41
Table 82: Annual Sales Analysis: 2004-2005 (In US$ Million) ........................................................ IV-41

BD Medical Systems Div. (USA) ......................................... IV-43
9. Bio-Rad Laboratories, Inc. (USA) ........................................ IV-44

Table 83: First Quarter Sales Analysis: 2005-2006 (In US$ Million) ........................................ IV-45
Table 84: First Quarter Sales Analysis By Segment: 2005-2006 (In US$ Million) .............................. IV-45
Table 85: Annual Sales Analysis: 2004-2005 (In US$ Million) ........................................................ IV-46
Table 86: Annual Sales Analysis By Quarter: 2004-2005 (In US$ Million) ........................................ IV-46
Table 87: Annual Sales Analysis By Segment: 2004-2005 (In US$ Million) ...................................... IV-46
Table 88: Annual Sales Analysis By Geographic Region: 2004-2005 (In US$ Million) ........................ IV-46

10. Biosafe Laboratories, Inc. (USA) .............................. IV-56
11. Bristol-Myers Squibb Company (USA) ........................ IV-57

Table 89: First Quarter Sales Analysis: 2005-2006 (In US$ Million) ........................................ IV-58
Table 90: Annual Sales Analysis: 2004-2005 (In US$ Million) ........................................................ IV-58

12. Cholestech Corporation (USA) ........................................ IV-62

Table 91: First Quarter Sales Analysis: 2006-2007 (In US$ Million) ........................................ IV-62
Table 92: Annual Sales Analysis: 2005-2006 (In US$ Million) ........................................................ IV-63

13. Dade Behring, Inc. (USA) ........................................ IV-64

Table 93: Half Year Sales Analysis: 2005-2006 (H1) (In US$ Million) ........................................ IV-65
Table 94: Half Year Sales Analysis By Segment: 2005-2006 (H1) (In US$ Million) .............................. IV-66
Table 95: Half Year Sales Analysis By Geographical Region: 2005-2006 (H1) (In US$ Million) ............... IV-66
Table 96: Annual Sales Analysis: 2004-2005 (In US$ Million) ........................................................ IV-66
Table 97: Annual Sales Analysis By Quarter: 2004-2005 (In US$ Million) ........................................ IV-66

Table 98: Annual Sales Analysis By Segment: 2004-2005 (In US$ Million) .................................... IV-67

8. Becton Dickinson and Company (USA) ........................ IV-39

Table 79: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ Million) ........................................ IV-41
Table 80: Half Yearly Sales Analysis By Quarter: 2005-2006 (H1) (In US$ Million) .............................. IV-41
Table 81: Half Yearly Sales Analysis By Segment: 2005-2006 (H1) (In US$ Million) ............................ IV-41
Table 82: Annual Sales Analysis: 2004-2005 (In US$ Million) ........................................................ IV-41

BD Medical Systems Div. (USA) ......................................... IV-43
9. Bio-Rad Laboratories, Inc. (USA) ........................................ IV-44

Table 83: First Quarter Sales Analysis: 2005-2006 (In US$ Million) ........................................ IV-45
Table 84: First Quarter Sales Analysis By Segment: 2005-2006 (In US$ Million) .............................. IV-45
Table 85: Annual Sales Analysis: 2004-2005 (In US$ Million) ........................................................ IV-46
Table 86: Annual Sales Analysis By Quarter: 2004-2005 (In US$ Million) ........................................ IV-46
Table 87: Annual Sales Analysis By Segment: 2004-2005 (In US$ Million) ...................................... IV-46
Table 88: Annual Sales Analysis By Geographic Region: 2004-2005 (In US$ Million) ........................ IV-46

10. Biosafe Laboratories, Inc. (USA) .............................. IV-56
11. Bristol-Myers Squibb Company (USA) ........................ IV-57

Table 89: First Quarter Sales Analysis: 2005-2006 (In US$ Million) ........................................ IV-58
Table 90: Annual Sales Analysis: 2004-2005 (In US$ Million) ........................................................ IV-58

12. Cholestech Corporation (USA) ........................................ IV-62

Table 91: First Quarter Sales Analysis: 2006-2007 (In US$ Million) ........................................ IV-62
Table 92: Annual Sales Analysis: 2005-2006 (In US$ Million) ........................................................ IV-63

13. Dade Behring, Inc. (USA) ........................................ IV-64

Table 93: Half Year Sales Analysis: 2005-2006 (H1) (In US$ Million) ........................................ IV-65
Table 94: Half Year Sales Analysis By Segment: 2005-2006 (H1) (In US$ Million) .............................. IV-66
Table 95: Half Year Sales Analysis By Geographical Region: 2005-2006 (H1) (In US$ Million) ............... IV-66
Table 96: Annual Sales Analysis: 2004-2005 (In US$ Million) ........................................................ IV-66
Table 97: Annual Sales Analysis By Quarter: 2004-2005 (In US$ Million) ........................................ IV-66

Table 98: Annual Sales Analysis By Segment: 2004-2005 (In US$ Million) .................................... IV-67

14. Diabetes Technologies, Inc. (USA) ............................ IV-87
15. Diazyme Laboratories (USA) ........................................ IV-88
16. Drew Scientific Group Plc (UK) ................................ IV-90
17. Flexsite Diagnostics, Inc. (USA) ............................... IV-92
18. Jokoh Co., Ltd. (Japan) ............................................. IV-92
19. Lifescan, Inc. (USA) ............................................... IV-93
20. OrSense (Israel) ............................................. IV-94
21. Pacific Diagnostics, Inc. (USA) ................................... IV-95

Table 100: Nine Months Sales Analysis: 2005-2006 (Nine Months Ended, March) (In US$ Million) .... IV-95

Table 101: Annual Sales Analysis: 2004-2005 (In US$ Million) ........................................ IV-96

Table 102: Annual Sales Analysis By Quarter: 2004-2005 (In US$ Million) .................................... IV-96

22. Pointe Scientific, Inc. (USA) ................................ IV-98
23. PolyMedica- Liberty Medical Supply (USA) ............ IV-99
24. Premier, Inc. (USA) ........................................ IV-100
25. Provalis Pte (UK) ........................................ IV-101

Table 103: Annual Sales Analysis: 2004-2005 (In £ Million) ................................................ IV-102

Table 104: Annual Sales Analysis By Segment: 2004-2005 (In £ Million) ..................................... IV-102

Table 105: Annual Sales Analysis By Geographic Region: 2004-2005 (In £ Million) ...................... IV-102

Provalis Diagnostics Ltd. (UK) ................................ IV-104
26. Roche Diagnostics (Schweiz) AG (Switzerland) .... IV-105
Roche Diagnostics Corporation (USA) ................ IV-107
Roche Diagnostics (Deutschland) GmbH (Germany) ... IV-108
27. Spectrx, Inc. (USA) ........................................ IV-109

Table 106: Annual Sales Analysis: 2004-2005 (In US$ Thousands) ........................................ IV-109

Table 107: Annual Sales Analysis By Geographic Region: 2004-2005 (In US$ Thousands) ........ IV-109

28. Sysmex Corporation (Japan) ............................... IV-111
29. Tosoh Bioscience, Inc. (USA) ............................. IV-117
30. Trinity Biotech Plc (Ireland) .............................. IV-118

Table 108: Annual Sales Analysis: 2004-2005 (In US$ Million) ........................................ IV-118

Table 109: Annual Sales Analysis By Geographic Region: 2004-2005 (In US$ Million) ............. IV-118

Table 110: Annual Sales Analysis By Geographic Region: 2004-2005 (In US$ Million) ........ IV-119

Table 111: Annual Sales Analysis By Geographic Region: 2004-2005 (In US$ Million) ........ IV-120